Status
Conditions
Treatments
About
Secondary hyperparathyroidism (HPT) is a known complication of chronic renal failure. Elevated concentrations of parathyroid hormone (PTH) play a role not only in the pathogenesis of renal bone disease, but also in the development of cardiovascular risk factors such as disturbed lipid metabolism, glucose intolerance, and hypertension. HPT is also known to play an important role in the development of structural abnormalities of both large arteries and the heart (left ventricular hypertrophy, interstitial fibrosis). In the last couple of years there has been increasing evidence from animal studies that the endothelium is a target organ of PTH.
Hypothesis: PTH has clinically relevant effects on renal hemodynamics, renal function and endothelial function.
Aims:
Enrollment
Sex
Ages
Volunteers
Inclusion and exclusion criteria
Inclusion Criteria:
Loading...
Central trial contact
Pieter Evenepoel, MD, PhD
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal